Crispr/cas-related methods and compositions for knocking out c5
US-2024415980-A1 · Dec 19, 2024 · US
Anti-C-MPL antibody and use thereof
US12590161B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12590161-B2 |
| Application number | US-202118038497-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 9, 2021 |
| Priority date | Nov 24, 2020 |
| Publication date | Mar 31, 2026 |
| Grant date | Mar 31, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a novel anti-C-MPL antibody and a use thereof, and specifically, to an anti-C-MPL antibody having an effect of increasing platelet production and its number through the maturation of megakaryocytes in the bone marrow, and a use thereof. The novel anti-C-MPL antibody (2R13) of the present invention is a polymer material and has a longer half-life than the conventional therapeutic agents, and it has the advantage of low self-antibody production and low immunogenicity as an antibody agent. In addition, it can be used as a therapeutic agent for thrombocytopenia by increasing the platelet level of patients suffering from chronic or complication-induced immune thrombocytopenia.
First claim
Opening claim text (preview).
The invention claimed is: 1 . An anti-c-MPL antibody or antigen-binding fragment thereof, comprising: a heavy chain variable region comprising a heavy chain CDR1 composed of amino acid sequence SEQ ID NO: 1, a heavy chain CDR2 composed of amino acid sequence SEQ ID NO: 2, and a heavy chain CDR3 composed of amino acid sequence SEQ ID NO: 3; and a light chain variable region comprising a light chain CDR1 composed of amino acid sequence SEQ ID NO: 4, a light chain CDR2 composed of amino acid sequence SEQ ID NO: 5, and a light chain CDR3 composed of amino acid sequence SEQ ID NO: 6. 2 . A method for preventing or treating thrombocytopenia comprising administering a pharmaceutical composition comprising the anti-c-MPL antibody or antigen-binding fragment thereof of claim 1 as an active ingredient to a subject in need thereof. 3 . The method for preventing or treating thrombocytopenia of claim 2 , wherein the pharmaceutical composition induces generation of megakaryocytes, activation of platelets and an increase in platelet count. 4 . A method for preventing or improving thrombocytopenia comprising administering a health functional food composition comprising the anti-c-MPL antibody or antigen-binding fragment thereof of claim 1 as an active ingredient to a subject in need thereof.
Assignees
Inventors
Classifications
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title
comprising antibodies · CPC title
- A61P7/06Primary
Antianaemics · CPC title
- C07K16/2866Primary
against receptors for cytokines, lymphokines, interferons · CPC title
Constant or Fc region; Isotype · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12590161B2 cover?
- The present invention relates to a novel anti-C-MPL antibody and a use thereof, and specifically, to an anti-C-MPL antibody having an effect of increasing platelet production and its number through the maturation of megakaryocytes in the bone marrow, and a use thereof. The novel anti-C-MPL antibody (2R13) of the present invention is a polymer material and has a longer half-life than the convent…
- Who is the assignee on this patent?
- Daegu Gyeongbuk Inst Science & Tech, Kosin Univ Industry Academy Cooperation, Univ Inje Ind Acad Coop Found
- What technology area does this patent fall under?
- Primary CPC classification A61P7/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).